Lilly says India already ran the GLP-1 price war, and Mounjaro grew anyway

A month of Mounjaro in India costs 13,000 to 25,000 rupees ¹; patent-expired copies of rival semaglutide go for 1,500 to 5,500 ¹. Nearly three dozen generic brands have piled in, and regulators have already raided a counterfeiting operation selling fake pens↗ ². Speaking in India this week, chief executive David Ricks delivered the first reported numbers from that experiment↗: Lilly's GLP-1 share eroded as the market exploded, and Mounjaro kept growing in volume and value, month by month ¹³.

A trillion rides on the premium tier

Lilly is the only drugmaker worth more than $1 trillion ¹. Quarterly revenue has more than doubled since 2023, from $9.5 billion to $23.0 billion in the quarter ended June 2026 ⁸. The bear case is that GLP-1 prices deflate faster than volume compounds. India is the only market where Lilly has reported post-patent share and growth numbers, and Ricks says Brazil and Canada show the same pattern qualitatively ¹³.

The premium tier held, on Lilly's telling

Ricks' read: generics recruited patients who would never have paid Mounjaro's price, in India, Brazil and Canada alike, while the premium tier held ¹³. Mounjaro became India's largest-selling medicine in its first year, a company-claimed number ¹. The lowest generic price points, he conceded, carry little real supply ¹.

"The lower the prices, the more people we tend to reach" ³ is the same logic behind the pricing arrangement Lilly signed with the Trump administration and the Change the Course pledge of 28 September↗, which targets parity between rich and poor countries by 2040, from a base where four of five incretin users live in wealthy countries while four of seven people with obesity live in low- and middle-income ones ³⁴.

The pipeline is the hedge

Retatrutide, the weekly triple agonist, cut average body weight 20.8% (49.6 lbs) over 80 weeks↗ on the top 12 mg dose across 1,152 patients with obesity and type 2 diabetes; 59.5% fell below the BMI threshold for obesity ⁵. Lilly files with the US FDA in the first quarter of 2027 ⁵. Foundayo, the daily pill that booked $98 million in second-quarter sales, cut cardiovascular death 53% against Lantus insulin ³⁴.

Novo Nordisk, down about 70% in two years, spent the last week of September buying back into the race: up to $3.92 billion in licensing commitments, €615 million of it upfront for Nanexa's quarterly-injection platform and $300 million upfront for Hengrui's weekly oral↗, both early-stage ⁶⁷.

No machine has discovered a drug yet

On AI, Ricks was blunt: no machine has discovered a drug, perhaps 15% of the needed biology is known, and Lilly's NVIDIA-built supercomputer is a bet on closing that gap ¹.

What the bulls cannot audit

The India result is the chief executive's account, unaudited, with no independent share data attached. India pays out of pocket, so a tenfold price gap is not a US copay structure. And volume can compound in an exploding market while the price per unit erodes underneath.

Q1 2027 is the date

Watch the retatrutide filing ⁵, Foundayo's Indian launch next year, with the lag cut from four years to one ¹, and whether Mounjaro volumes hold as generic supply stabilises. Ricks' summary is the trade itself: "By that time, we'll have many other premium choices" ¹.